Desmopressin and bleeding time in patients with cirrhosis.

Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, McIntyre N

British medical journal (Clinical research ed.)1 Nov 1985Cited by 56 (Europe PMC)

PMID3933677PMCIDPMC1419032DOI10.1136/bmj.291.6506.1377PepBankPUB-03933677

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly shortened bleeding time versus baseline in both groups.
In plain wordsIn chronic liver disease patients, desmopressin shortened bleeding time versus baseline in both groups.
Peptide
Desmopressin
Outcome
DecreaseBleeding time versus baseline
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Desmopressin acetate significantly shortened the bleeding time compared with basal values in both groups and compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367701
02HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly shortened bleeding time versus placebo.
In plain wordsIn chronic liver disease patients, desmopressin shortened bleeding time versus placebo.
Peptide
Desmopressin
Outcome
DecreaseBleeding time versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Desmopressin acetate significantly shortened the bleeding time compared with basal values in both groups and compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367702
03HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly decreased partial thromboplastin time.
In plain wordsIn chronic liver disease patients, partial thromboplastin time decreased after desmopressin.
Peptide
Desmopressin
Outcome
DecreasePartial thromboplastin time
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367703
04HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly decrease prothrombin time.
In plain wordsIn chronic liver disease patients, prothrombin time did not decrease significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeProthrombin time
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367704
05HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly increased factor VIII and its components.
In plain wordsIn chronic liver disease patients, factor VIII and its components increased after desmopressin.
Peptide
Desmopressin
Outcome
IncreaseFactor VIII
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367705
06HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly increased von Willebrand factor.
In plain wordsIn chronic liver disease patients, von Willebrand factor increased after desmopressin.
Peptide
Desmopressin
Outcome
Increasevon Willebrand factor
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367706
07HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly increased ristocetin cofactor activity.
In plain wordsIn chronic liver disease patients, ristocetin cofactor activity increased after desmopressin.
Peptide
Desmopressin
Outcome
IncreaseRistocetin cofactor activity
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367707
08HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly increase factor VII.
In plain wordsIn chronic liver disease patients, factor VII did not increase significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeFactor VII
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367708
09HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly increase factor IX.
In plain wordsIn chronic liver disease patients, factor IX did not increase significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeFactor IX
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367709
10HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly increase factor X.
In plain wordsIn chronic liver disease patients, factor X did not increase significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeFactor X
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367710
11HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly increase factor XI.
In plain wordsIn chronic liver disease patients, factor XI did not increase significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeFactor XI
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367711
12HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin did not significantly increase factor XII.
In plain wordsIn chronic liver disease patients, factor XII did not increase significantly after desmopressin.
Peptide
Desmopressin
Outcome
No significant changeFactor XII
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in partial thromboplastin time (but not prothrombin time) and significant increases in factor VIII and its components, von Willebrand factor and ristocetin cofactor activity, but not in factors VII, IX, X, XI, or XII.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367712
13HumanNon-randomized trialSafety outcome
In chronic liver disease patients, no important side effects were seen with desmopressin.
In plain wordsIn chronic liver disease patients, no important side effects were seen with desmopressin.
Peptide
Desmopressin
Outcome
Not applicableImportant side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
No important side effects were seen.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367713
14HumanNon-randomized trialActivity measurement
In chronic liver disease patients, desmopressin significantly increased the percentage of higher molecular weight von Willebrand factor multimers.
In plain wordsIn chronic liver disease patients, desmopressin increased the proportion of larger von Willebrand factor multimers.
Peptide
Desmopressin
Outcome
IncreaseHigher molecular weight vWF multimers
Study
n: not reported in source
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
It was normal, but after administration of desmopressin acetate the percentage of multimers of higher molecular weight increased significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
Desmopressin acetate 0.3 microgram/kg was given intravenously to nine patients with chronic liver disease and to a further six such patients in a double blind controlled study versus placebo.
Report a problemFND-0393367714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.